Sai-Hong Ignatius Ou

Sai-Hong Ignatius Ou is a pioneer in identifying and treating ROS1 rearrangements and MET exon 14 skipping mutations in NSCLC. He led early clinical trials demonstrating the activity of crizotinib in ROS1-positive tumors and contributed to development of more potent next-generation ROS1 inhibitors. His work on MET exon 14 skipping mutations helped establish tepotinib and capmatinib as approved therapies. He has built a comprehensive molecular profiling program for rare driver mutations in NSCLC.